|
Published by: Datamonitor
Published: Aug. 28, 2001 - 69 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
Global Director of CNS
EXECUTIVE SUMMARY
Scope
Key metrics
TABLE OF CONTENTS
EPIDEMIOLOGY
Definition
Diagnostic criteria
Comorbidities
Mood disorders
Anxiety disorders
Substance-related disorders
Patient potential
Prevalence
Epidemiological conclusion
CLINICAL PRACTICE
Introduction
Diagnosis
Guidelines in existence
Physician diagnosis rate
Treatment
Breakdown of SAD within anxiety disorders
First line SAD treatment
Overall SAD treatment
Influence on SAD marketing
The strength of efficacy data
The presentation of comorbid disorders
The weak position of paroxetine
CURRENT SAD MARKET
Antidepressant use in SAD
The lead compound
Paxil
Major rivals
Zoloft
Luvox
Other players
Celexa/Cipramil
Effexor
Serzone
Prozac
MAOIs
Anxiolytic use in SAD
Benzodiazepines
Buspar
Conclusion
The global SAD market 2001
THE FUTURE DECODED
Unmet needs in treating SAD
The SAD R&D pipeline
Fluvoxamine CR
Venlafaxine
Sertraline
Pregabalin
NKP 608
Gabapentin
The SAD market 2001-2008
Factors influencing the future SAD market
Future drug launches
SAD market forecasts to 2008
SAD market forecast 2005
SAD market forecast 2008
Conclusion
APPENDIX
Datamonitor's Central Nervous System Business Unit
Table of tables
Epidemiology
Clinical trials
Websites
R&D research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification and quality control
Physician research questionnaire
Diagnosis
Treatment
Unmet needs
Pricing data
Introduction
Source prices
Ex-manufacturer, wholesaler and retail prices
Data validation and margin calculation
Quality control
Patent expiries
AbstractDatamonitor's Strategic Perspectives 2001: Anxiety Disorders series of eight reports form a comprehensive review of major anxiety and eating disorder markets. Each report utilizes primary research data in the seven leading healthcare markets and investigates the current state of affairs in each market. Furthermore they provide an in-depth analysis of the current pipeline, estimated drug launches and the future direction of each anxiety disorder. Anxiety Disorders covered Eating Disorders (Anorexia Nervosa and Bulimia Nervosa)Generalized Anxiety DisorderObsessive Compulsive Disorder Panic DisorderPhobias (Specific Phobia and Agoraphobia)Post Traumatic Stress DisorderPremenstrual Dysphoric DisorderSocial Anxiety Disorder
Get Full Details About This Report >>
|
